Interpretation of the 2023 Chinese Guidelines for the diagnosis and treatment of drug-induced liver injury
Drug-induced liver injury(DILI)is a significant adverse drug reaction that severely threatens patients'lives and health.In recent years,there has been remarkable progress in the field of DILI research,with the introduction of many perspectives and evidence.In 2023,the Hepatology Branch of the Chinese Medical Association and the Drug-Induced Liver Disease Group updated and released the"2023 Chinese Guidelines for the Diagnosis and Treatment of Drug-Induced Liver Injury."The new guidelines,based on the latest evidence,provide guiding recommendations on important clinical issues such as definition,clinical staging,diagnosis and differential diagnosis,treatment and prevention,prognosis,and follow-up of DILI.This article aims to help clinical practitioners understand the guidelines more comprehensively and deeply by interpreting the key content and applying it to guide clinical practice.
NETL
NSTL
万方数据
